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Background: Endothelial dysfunction of the coronary arteries caused by oxidative stress plays an impor-
tant role in the pathogenesis of coronary vasospasm. However, it is not clear whether circulating
biomarkers for oxidative stress are altered after coronary vasospasm. We investigated temporal changes
in the levels of oxidative stress biomarkers after coronary vasospasm induced by intracoronary acetyl-
choline provocation testing, resulting in transient myocardial ischemia.
Methods and results: Thirty consecutive patients with suspected vasospastic angina pectoris (VSAP) were
enrolled in the study. Patients were categorized into the VSAP-positive group (n=14) and the VSAP-
negative group (n=16) on the basis of test results. Serum samples were examined for the levels of the
oxidative stressmarkers 4-hydroxynonenal (HNE) andnitrotyrosine (NT) before, and15min, 3h, and12h
after theprovocation test. The serumHNE levelsdidnot change ineither groupafter the test. The serumNT
levels in the VSAP-positive group signiﬁcantly increased at 3h and 12h after the test (11.3±3.3g/ml
at 3h, p=0.015, and 12.1±5.7g/ml at 12h, p=0.03), as compared with baseline (8.1±3.2g/ml). In
the VSAP-negative group, the serum NT levels signiﬁcantly decreased from baseline at each of the 3 time
points.
Conclusions: Serum NT signiﬁcantly increased after coronary vasospasm induced by acetylcholine provo-
cation, suggesting that serum NT could be a biomarker of transient myocardial ischemia and could
ment
© 2contribute to the develop
ntroduction
Coronary vasospasm is involved in the pathophysiology of vari-
nt angina, acute myocardial infarction, and sudden cardiac death
1–5]. Endothelial dysfunction of the coronary arteries caused by
he overproduction of oxidative stress plays an important role in
he pathogenesis of coronary spasm [6–10]. Episodes of vasospastic
ngina pectoris (VSAP) are characterized by transient myocardial
schemia caused by total or near-total occlusion of a coronary
rtery. Oxidative stress produced by ischemia/reperfusion injury is
nown to oxidize lipids and proteins, thereby inducing endothelial
∗ Corresponding author at: Department of Cardiology, Kanazawa Medical Univer-
ity, 1-1 Daigaku, Uchinada, Kahoku, Ishikawa 920-0293, Japan.
el.: +81 76 286 2211; fax: +81 76 286 3780.
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914-5087/$ – see front matter © 2014 Published by Elsevier Ltd on behalf of Japanese Co
ttp://dx.doi.org/10.1016/j.jjcc.2013.11.017of VSAP.
014 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.
dysfunction, atherosclerotic lesions, and myocardial stunning
[11–13]. 4-Hydroxynonenal (HNE) is a well-known lipid peroxide
produced during cardiac ischemia [14]. Nitrotyrosine (NT) is
produced by the modiﬁcation of protein tyrosine residues by
peroxynitrite generated from the reaction of nitric oxide (NO) and
superoxide [15]. HNE resides in atherosclerotic lesions and partic-
ularly in foam cells, whereas HNE enhances metalloproteinase-2
production in vascular smooth muscle cells and may underlie
plaque rupture [16,17]. Peroxynitrite production in the endothe-
lium decreases NO bioavailability and prostacyclin production,
decreases vasorelaxation, and changes the vascular tone [18–21],
and endothelial dysfunction and peroxynitrite formation are
early events in angiotensin-induced cardiovascular disorders [22].
However, no clinical evidence has been provided for HNE and NT
in the pathogenesis of VSAP, despite the potential importance
of oxidative stress. This study aimed to investigate the effect of
oxidative stress on the course of VSAP. To this end, we investigated
llege of Cardiology.
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None of the studied patients had major complications such as
ventricular rhythm disturbance, refractory spasm, or myocardial
infarction. The frequency of prior use of nitrates and/or calcium
channel blockers before the test was lower in the VSAP-negative
Table 1
Clinical characteristics of the study patients.
VSAP-positive
group
VSAP-negative
group
p-Value
Total population, n 14 16
Age, years (means± SD) 66±8.2 63±11 0.62
Men, n (%) 5 (36) 9 (56) 0.34
Coronary risk factors, n (%)
Hypertension 7 (50) 7 (44) 0.73
Hyperlipidemia 7 (50) 6 (38) 0.49
Diabetes mellitus 1 (7) 1 (6) 0.92
Smoking 4 (29) 2 (13) 0.27
Chest pain, n (%) 9 (64) 0 (0)
Provoked form, n (%)
100% 2 (14)
99% 12 (86)
Provoked coronary, n (%)
LAD 9(64)
LCX 1(7)
RCA 7(50)
Medication at admission, n (%)
Nitrate 7 (50) 3 (19) 0.07
CCB 9 (64) 5 (31) 0.07
Nitrate and/or CCB 12 (86) 6 (38) 0.007
Statins 3 (21) 2 (13) 0.51
Aspirin 5 (36) 4 (25) 0.64K. Tanabe et al. / Journal
emporal changes in HNE and NT levels after coronary vasospasm
nduced by intracoronary acetylcholine provocation testing in
atients with VSAP and in controls.
ethods
ubjects
Thirty-two consecutive Japanese patients suspected of having
SAP, who had atypical chest pain at rest, were admitted to our
ospital and diagnostic coronary angiography was performed. Two
atientswhose coronary angiography results showed≥50%organic
tenosis were excluded from this study. Therefore, we performed
he intracoronary acetylcholine provocation test on the remaining
0 patients who did not have any signiﬁcant organic stenosis.
The study protocol conformed to theDeclaration of Helsinki and
as approved by the Human Ethics Committee of Kanazawa Medi-
al University, and all patients provided written informed consent.
atheterization procedure, angiographic analysis, and blood
ample collection
At least 24h before the provocation test, nitrates, calcium
hannel blockers, and other anti-anginal drugs, except sublingual
itroglycerin, were withdrawn from all patients after admission.
ll coronary angiography procedures were performed through a
emoral approach by using the standard Judkins technique after
he administration of 2000U of heparin in the morning. In the
rovocation test, acetylcholinewas injected through a catheter into
he right coronary artery at a dose of 20 or 50g and into the
eft coronary artery at 50 or 100g, each within 1min. At 3min
rom the initiation of each injection, angiography was performed.
standard 12-lead electrocardiogram was recorded continuously
o assess ST-segment shift. The patients informed the examiner
f they experienced chest pain during the provocation test. When
ngina developed with chest pain and/or ST-segment shift, angiog-
aphy was immediately performed, and subsequently 0.25mg of
itroglycerin was injected into the responsible coronary artery
o relieve the symptoms. The heart rate and blood pressure of
ach patient were monitored continuously during the procedure.
emodynamic variables were measured before and at the end
f acetylcholine infusion. The double product was calculated by
ultiplying the systolic blood pressure and the heart rate at the
ame time point. Coronary vasospasm was deﬁned as the tran-
ient total or near total (>90%) occlusion of the provoked coronary
rtery, which was reversible with nitroglycerin. Patients were
ategorized as test-positive if they developed angina with ST-
egment shift and chest pain and showed coronary vasospasm
n coronary angiography. Among the 30 patients subjected to
he intracoronary acetylcholine provocation test, 14 were posi-
ive (VSAP-positive group), and 16 were negative (VSAP-negative
roup). After the provocation, 0.25mg of nitroglycerinwas injected
nto both coronary arteries of VSAP-negative patients or the non-
esponsible coronary artery of VSAP-positive patients to obtain
aximal coronary dilation, and ﬁnal angiography was performed.
lood samples were collected from the femoral sheath before and
5min after the provocation test. Follow-up blood samples were
btained fromanantecubital vein3 and12hafter completionof the
rovocation test. Serum samples were prepared from each blood
ample through centrifugation and were stored at −80 ◦C until
ssay.easurement of HNE and NT in the serum of patients
Time-resolved ﬂuoroimmunoassay, which is 100 times more
ensitive than conventional enzyme-linked immunosorbent assay,iology 64 (2014) 86–90 87
was performed to measure HNE and NT, as previously reported
[23–25]. The ﬂuorescence intensity was measured at 340nm exci-
tation and 615nm emissions, using an Arvo SX multilabel counter
(Perkin-Elmer Life Sciences, Boston, MA, USA).
Statistical analyses
Data are expressed as mean± SD. The Student’s t test was used
to compare the values between the 2 groups. ANOVA for repeated
measureswas used to assess the differences in the valuesmeasured
at baseline and at each of the 3 time points. Categorical variables
in the patient’s clinical background were compared using the 2
test or a nonparametric test. Data analysis was performed using
StatView software, version 5.0 (SAS Institute, Cary, NC, USA) and R
software, version 2.5.1 (http://www.r-project.org/). Statistical sig-
niﬁcance was deﬁned as p<0.05.
Results
Clinical characteristics of the study group
Table 1 shows the clinical characteristics of patients in theVSAP-
positive and VSAP-negative groups. No signiﬁcant differenceswere
found between the 2 groups with respect to mean age, sex, and the
prevalence of coronary risk factors such as hypertension, hyperlipi-
demia, diabetes mellitus, or smoking status. In the VSAP-positive
group, 9 (64%) patients experienced chest pain during the provo-
cation test. Two (14%) and 12 (86%) patients showed total and
near-total occlusion, respectively, on the coronary angiogram. All
patients with total occlusion showed transient ST-segment ele-
vation, whereas all patients with near-total occlusion showed
transient ST-segment depression. No patients in the VSAP-negative
group had signiﬁcant narrowing of the involved coronary artery,
electrocardiographic changes, or chest pain during the procedure.ACEI/ARB 1 (7) 5 (31) 0.08
ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor block-
ers; CCB, calcium channel blockers; LAD, left anterior descending coronary artery;
LCX, left circumﬂex coronary artery; RCA, right coronary artery.
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Fig. 1. Temporal changes in serum (A) HNE and (B) NT levels after the acetyl-
choline provocation test in the VSAP-positive (open circles) and VSAP-negative
(solid circles) groups. Bar represents mean± SD values. *p<0.05 versus the base-
line value of the VSAP-positive group, †p<0.001 versus the baseline value of the
#8 K. Tanabe et al. / Journal
roup than in the VSAP-positive group (p=0.007). However, no
igniﬁcant differences were observed between the 2 groups in
he use of other cardiovascular medicines such as statins, aspirin,
ngiotensin-converting enzyme inhibitors, or angiotensin II recep-
or blockers. None of the studied patients were premedicated with
-blockers.
emodynamic variables
The hemodynamic variables are shown in Table 2. Baseline val-
es of heart rates and mean blood pressure in patients with VSAP
ere not signiﬁcantly different from those in control patients.
he heart rate, mean blood pressure, and double products were
ncreased from baseline at the end of the acetylcholine infusion
n both patient groups. However, no signiﬁcant differences were
bserved between the 2 groups in the hemodynamic variables at
he end of acetylcholine infusion into the coronary artery.
lterations in serum HNE and NT levels during the time course
The changes in the HNE and NT levels after the provocation
est in the VSAP-positive and VSAP-negative groups are shown
n Fig. 1A and B, respectively. No signiﬁcant differences were
ound between the baseline serum HNE levels of the VSAP-positive
nd VSAP-negative groups. Furthermore, no signiﬁcant changes
ere observed in the serum HNE levels of both groups during
heir time courses. The baseline serum NT levels were signiﬁ-
antly lower in the VSAP-positive group than in the VSAP-negative
roup (8.1±3.2g/ml vs 11.5±3.3g/ml, respectively, p=0.008).
s compared with baseline values (8.1±3.2g/ml), serum NT lev-
ls in the VSAP-positive group signiﬁcantly increased at 3h to 12h
fter the test (11.3±3.3g/ml at 3h,p=0.015, and12.1±5.7g/ml
t 12h, p=0.03). In contrast, serum NT levels in the VSAP-negative
roup signiﬁcantly decreased from baseline at each of the 3 time
oints.
nﬂuence of prior medications on serum NT levels at baseline and
edications on serum NT levels after the provocation test
We addressed whether prior medications, especially nitrates
nd calcium channel blockers, caused the lower basal levels of
erum NT in the VSAP-positive group than those in the VSAP-
egative group. Among all studied patients, 9 were treated with
itrates, 14 with calcium channel blockers, and 18 with nitrates
nd/or calcium channel blockers on admission. Pretreatment with
ither nitrates or calcium channel blockers did not inﬂuence the
aseline serum NT levels. However, the baseline serum NT lev-
ls were signiﬁcantly lower in patients premedicated with nitrates
nd/or calcium channel blockers than in patients without nitrates
Table 2
Changes in hemodynamic variables.
Baseline
VSAP-positive
HR (beats/min)
MBP (mm Hg)
Double product
68 ± 16
88 ± 11
8740 ± 2510
64 ± 7
84 ± 10
7528 ± 1212
VSAP-negative
HR (beats/min)
MBP (mm Hg)
Double product
Data are means± SD. HR, heart rate; MBP, mean blood pressuVSAP-negative group, and p<0.01 versus the VSAP-negative group at baseline.
HNE, 4-hydroxynonenal; NT, nitrotyrosine; VSAP, vasospastic angina pectoris.
or calcium channel blockers (8.7±3.1g/ml vs 11.8±3.8g/ml,
respectively, p=0.02) (Fig. 2). We also examined whether medica-
tions after the provocation test inﬂuenced serum NT levels in the
VSAP-negative patients, because all VSAP-positive patients were
administered with nitrates and calcium channel blockers imme-
diately after the test. Among the VSAP-negative patients, two
received calcium channel blockers, ﬁve received nitrates and cal-
cium channel blockers, and nine were not given any drugs. Serum
NT levels didnot signiﬁcantly differ betweenpatients givennitrates
and/or calcium channel blockers and those without medication at
each of the three time points (data not shown).
After acetylcholine infusion
70 ± 15
90 ± 13
8800 ± 2980
66 ± 16
90 ± 17
8048 ± 1785
NS
re; VSAP, vasospastic angina pectoris.
K. Tanabe et al. / Journal of Card
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epresents mean± SD values. NT, nitrotyrosine; VSAP, vasospastic angina pectoris.
iscussion
In this clinical study, we showed that the coronary spasm
nduced by the intracoronary acetylcholine provocation test could
nduce elevation in serum NT levels in patients with VSAP. In con-
rast, serum HNE levels in both groups remained unchanged at all
ime points after the provocation test. This is the ﬁrst study to show
linical evidence for the contribution of peroxynitrite in the patho-
enesis of VSAP. Additionally, NT rather than HNE is recommended
or the evaluation of oxidative stress in VSAP.
NO is synthesized from l-arginine by endothelial NO synthase
n vascular endothelial cells, and induces smooth muscle relax-
tion and vascular dilation in response to endothelium-dependent
asodilators such as acetylcholine [26,27]. Ischemia/reperfusion
nduces enhanced production of reactive oxygen species (ROS) and
O in the vasculature [28]. Subsequently, peroxynitrite generated
rom the reaction of ROS and NO induces endothelial dysfunc-
ion, atherosclerotic lesions, andmyocardial stunning [12,15,29]. In
his diverse pathological setting, endothelial NO synthase (eNOS)
roduces less NO andmore ROS through eNOS uncoupling, thereby
roducing peroxynitrite [30]. In the pathogenesis of coronary
asospasm, endothelial dysfunction of coronary arteries, due to
eﬁcient NO and excessive peroxynitrite, is supposed to play an
mportant role [6,7]. However, there has been no solid evidence
or this hypothesis. Since direct measurement of short-lived ROS,
O, and peroxynitrite is impossible in the clinical setting, stable
roducts such as HNE and NT have been measured [31]. In addi-
ion to the effect of peroxynitrite, NT alone can induce endothelial
ysfunction [32].
For theﬁrst time,wedemonstrated the sustainedelevationofNT
evel after coronary spasm, indicating that peroxynitrite is involved
n coronary vasospasm and the pathogenesis of VSAP, as previously
roposed [33]. The high NT levels lasted for at least up to 12h after
he provocation with acetylcholine, an established reagent to eval-
ate endothelial function through eNOS. This is striking, as ROS and
O are unstable, and the sustained elevation of NT implies per-
istent activation of uncoupled eNOS that generates peroxynitrite
nd NT, and would induce sustained coronary spasm until nitrate
as administered. Since nitroglycerin stimulates NO production,
he high NT levels in the VSAP-positive patients may have been
erived at least partly from nitroglycerin.As few biomarkers can detect transient myocardial ischemia,
erum NT could be a biomarker for detecting this condition in
atients with VSAP. One study has found that plasma NT does not
ncrease at 30min after a positive exercise tolerance test [34]. Theiology 64 (2014) 86–90 89
decreased duration and extent of ischemia after exercise might
have been insufﬁcient to elevate NT levels in that study. Other-
wise, the sensitivity of themethod used tomeasure NT in our study
was superior to that used in that study, which might explain the
discrepancy between our results and those of others.
Interestingly, we found that serum NT levels in the VSAP-
negative group decreased from the baseline at all time points after
the test. Some of the components that were used in the provoca-
tion test and medications after the test might have inﬂuenced this
result. As NO functions as a scavenger of reactive oxygen species
[35–37], it is plausible that the NO released from endothelium by
the acetylcholine-induced activation of eNOS, and theNOproduced
by nitroglycerin, may have decreased the serum NT levels. Because
changes in serumNT levels after the testwere similar in thepatients
withnitrate and/or calciumchannel blockers andwithout anymed-
ications, medications after the test might not inﬂuence changes in
the serum NT levels.
Because VSAP is closely related to oxidative stress-induced
endothelial dysfunction [33], we hypothesized that the HNE and
NT levels at baseline might be higher in VSAP-positive patients
than in VSAP-negative patients. Unexpectedly, the baseline serum
NT levels were signiﬁcantly lower in the VSAP-positive group than
in the VSAP-negative group in this study. We therefore deter-
mined whether treatment with nitrates and/or calcium channel
blockers with antioxidant activity affected the levels of NT in
the 2 groups. The frequency of prior use of nitrates and/or cal-
cium channel blockers on admission was signiﬁcantly lower in
the VSAP-negative group than in the VSAP-positive group. Fur-
thermore, in all studied patients, the serum NT levels at baseline
were signiﬁcantly lower in patients premedicated with nitrates
and/or calcium channel blockers than in patients without nitrates
or calcium channel blockers (Fig. 2). These ﬁndings suggest that
the baseline serum NT levels were inﬂuenced by premedication
with nitrates and calcium channel blockers, and the effect lasted at
least 24h from the withdrawal of these drugs before the provo-
cation test. However, even though basal NT levels were lower
in the VSAP positive group, myocardial ischemia occurring after
vasospasm will generate a sufﬁcient amount of superoxide to
surpass the scavenger effects of nitrates and calciumchannel block-
ers, and superoxide reacting with NO would yield peroxynitrite
that would lead to NT production after vasospasm. During arachi-
donic acid oxidation and cardiac ischemia, over 100-fold more
HNE than malondialdehyde is generated [14,38]. On the other
hand, NT is generated under oxidative stress with myocardial
ischemic reperfusion injury [39]. Thus, we considered HNE and
NT as candidate oxidative stress markers of transient myocardial
ischemia after vasospasm. However, serum HNE levels did not
change after the test irrespective of the presence of myocardial
ischemia. Coronary vasospasm provoked by the test was relieved
within 1min after the intracoronary injection of nitroglycerin. This
short duration of transient ischemiamight not allow sufﬁcient gen-
eration of superoxide anions, leading to increased generation of
HNE. In addition, aldehyde dehydrogenase 2 that degrades HNE
might be involved in the smaller elevation of HNE after vasospasm
[14].
This study has some limitations. First, we examined alterations
in the levels of serumHNEandNTuntil 12h after the test, and found
that serum NT levels peaked at 12h after the test. A previous study
reported that plasma NT levels peaked at 24h after percutaneous
coronary intervention in patients with acute myocardial infarction
[40]. Therefore, the response of these markers to transient myocar-
dial ischemia needs to be examined at a later time point after the
test; however,we couldnot perform this becauseof ethical reasons.
Second, it remains to be clariﬁedwhethermyocardial ischemiawas
practically induced by coronary spasm. In this study, the double
product, an index of myocardial oxygen demand, did not show a
9 of Car
s
p
d
o
a
p
m
N
t
d
r
s
c
c
e
s
r
m
i
p
o
o
C
A
e
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[0 K. Tanabe et al. / Journal
igniﬁcant difference between VSAP-positive and VSAP-negative
atients at the end of acetylcholine infusion. To clarify myocar-
ial ischemia except for ST-segment changes on electrocardiogram,
ther parameters for the detection of ischemia, such as pulmonary
rtery wedge pressure, left ventricular end diastolic pressure, and
roduction of lactate, need to be evaluated. Third, to compare the
echanisms of NT elevation after vasospasm with those of HNE,
O levels and endothelial function should be evaluated after the
est in patients with VSAP. The short half-life of NO has rendered it
ifﬁcult to directlymeasure in vivo, but newmethods ofmeasuring
eal-time NO levels in the coronary circulation using catheter-type
ensors have been developed [41]. Further studies are required to
larify changes inNO levels after inducingvasospasmvia theprovo-
ation test, as well as the association between NT levels and the
xtent of endothelial dysfunction. Finally, we used a small study
ample size. Further studies with a large sample population are
equired to evaluate whether serum NT level is a clinically useful
arker for the detection of transient ischemia.
In conclusion, NT, an oxidative stress biomarker, signiﬁcantly
ncreased after coronary vasospasm induced by acetylcholine
rovocation testing, suggesting that serumNTcouldbe abiomarker
f transientmyocardial ischemia and could contribute to the devel-
pment of VSAP.
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